About Vela Diagnostics
Vela Diagnostics is a company based in Singapore (Singapore) founded in 2011 was acquired by Luye Medical in April 2016. Vela Diagnostics offers products and services including SX101, SQ301, SA201, SARS-CoV-2 Test, and OncoKey. Vela Diagnostics operates in a competitive market with competitors including Nanopore, PacBio, Omniome, Complete Genomics and NeuMoDx, among others.
- Headquarter Singapore, Singapore
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vela Diagnostics Holding Pte. Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$225 K (USD), Grant
Apr 21, 2020
-
Investors
BARDA
& 1 more
-
Employee Count
Not available
-
Acquired by
Luye Medical
(Apr 06, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vela Diagnostics
Vela Diagnostics offers a comprehensive portfolio of products and services, including SX101, SQ301, SA201, SARS-CoV-2 Test, and OncoKey.
Instrument for next-generation sequencing and workflow automation
Device for NGS applications in laboratory testing
System for real-time PCR and sample analysis
Assay for detecting SARS-CoV-2 virus in samples
Panel for oncology genetic analysis and reporting
Funding Insights of Vela Diagnostics
Investors in Vela Diagnostics
Vela Diagnostics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include BARDA and Luye Medical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
BARDA is focused on developing medical countermeasures for public health security.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Vela Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vela Diagnostics
Investment portfolio details for Vela Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vela Diagnostics
Detailed financials for Vela Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vela Diagnostics Comparisons
Peer comparison for Vela Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vela Diagnostics
Vela Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nanopore, PacBio, Omniome, Complete Genomics and NeuMoDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Nanopore-based electronic systems for single-molecule analysis are developed.
|
|
| Locked | Locked | Locked |
Instrument systems and software for single-molecule real-time sequencing are developed.
|
|
| Locked | Locked | Locked |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| Locked | Locked | Locked |
DNA sequencing platform for human genome analysis is developed.
|
|
| Locked | Locked | Locked |
Developer of a platform for low cost molecular testing
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing technologies for applied genomic testing and medical sequencing
|
Detailed competitors of Vela Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vela Diagnostics
Complete news archive for Vela Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vela Diagnostics
Vela Diagnostics was founded in 2011 and raised its 1st funding round 9 years after it was founded.
Vela Diagnostics is headquartered in Singapore, Singapore.
Sam Dajani is the current CEO of Vela Diagnostics.
Vela Diagnostics was founded in 2011 in Singapore and operates in the molecular diagnostics sector. Integrated solutions for diagnosing infectious diseases and cancer are provided through PCR and Next-Generation Sequencing platforms. Products such as the Sentosa SX101 instrument, Rotor-Gene Q system, labware, consumables, and PCR reagents are offered to support testing for infectious and oncologic targets. Operations focus on laboratory-based molecular testing worldwide.
Vela Diagnostics offers SX101, SQ301, SA201, SARS-CoV-2 Test, and OncoKey.
Vela Diagnostics has 2 investors. Key investors include BARDA, and Luye Medical.